Anne-Sophie Bidaux

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers

Aurélien Voissière, Carlos Gomez‐Roca, Sylvie Chabaud et al. · Science Translational Medicine · 2024 · 54 citations

Medicine, Oncology, Pharmacology +17

MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).

Philippe A. Cassier, Gwenaëlle Garin, Lauriane Eberst et al. · Journal of Clinical Oncology · 2019 · 48 citations

Medicine, Oncology, Pharmacology +17

MEVITEM—a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation

Didier Frappaz, Marc Barritault, Laure Montané et al. · Neuro-Oncology · 2021 · 38 citations · Full text

Medicine, Oncology, Pharmacology +13

A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors

Philippe A. Cassier, Lauriane Eberst, G. Garin et al. · Annals of Oncology · 2019 · 17 citations

Medicine, Oncology, Pharmacology +17

A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)

David Kryza, Armelle Vinceneux, Anne-Sophie Bidaux et al. · BMC Cancer · 2024 · 17 citations · Full text

Medicine, Nuclear Medicine, Oncology +17